Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate : Experience From Croatian Reference Center for Viral Hepatitis (CROSBI ID 177433)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kurelac, Ivan ; Papić, Neven ; Sakoman, Slavko ; Orban, Mirjana ; Dušek, Davorka ; Ćorić, Marijana ; Vince, Adriana Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate : Experience From Croatian Reference Center for Viral Hepatitis // Hepatitis monthly, 11 (2011), 12; 986-992. doi: 10.5812/kowsar.1735143X.779

Podaci o odgovornosti

Kurelac, Ivan ; Papić, Neven ; Sakoman, Slavko ; Orban, Mirjana ; Dušek, Davorka ; Ćorić, Marijana ; Vince, Adriana

engleski

Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate : Experience From Croatian Reference Center for Viral Hepatitis

Hepatitis C virus (HCV) is the major infectious disease agent among injecting drug users (IVDUs). However, most of the IVDUs are still excluded from the treatment. The aim of this study was to examine the treatment course, adherence, tolerability and safety profiles and SVR rates in IVDUs compared to non-IVDUs. Demographic and clinical data were collected from medical records of 345 adult patients diagnosed with chronic hepatitis C (CHC) who were treated with a PEG-IFN-α and ribavirin in Croatian Reference Center for Viral Hepatitis in Zagreb in period between January 2003 and January 2010. Efficacy, safety and tolerability treatment profiles were analyzed in IVDUs versus non IVDUs. Positive predictors for treatment outcome were evaluated by univariate and multivariate logistic regression. A total of 106 (30.46%) IVDUs were recognized. The IVDUs were characterized by predominated male sex (81.13% vs. 52.30%, p=0.0001), younger age (32.46±5.33y vs. 46.12±11.48y, p=0.0001), lower fibrosis and HAI score (measured by ISHAK) and shorter duration of infection (8.98±5.87 vs. 16.79±8.99y, p=0.0001) than non-IVDU group. In IVDUs genotype 1a (24.52%) and 3a (38.68%) were predominant. There were no differences in completion rate between two groups. IVDUs achieved significantly higher rates of overall SVR (70.75 vs 51.04, p<0.0009) and in genotypes 1 and 4 (65.08% vs. 48.73%, p=0.0294) versus non-IVDUs. Treatment discontinuation rates due to side-effects were not significantly different in IVDUs and non IVDUs (2.83% vs. 7.11%, p=0.1390). IVDU group had higher rate of lost to follow up (13.21% vs. 4.60%, p=0.0071). There were no statistical differences in SVR rate between IVDUs with, or without substitution therapy (55.55 vs. 74.62%, p=0.0866). Independent predictors of SVR were age < 40 years and genotypes 2 and 3. Type of PEG-IFN-α was not associated with SVR. Treatment of CHC in IVDUs should strongly be encouraged as they have positive predictors for achieving SVR such as younger age, shorter duration of infection, consequently favorable histological stage of the disease, and good adherence to treatment. There is no difference in safety and tolerability profile of treatment in IVDUs compared to patients with no history of drug abuse.

addiction; intravenous drug users; viral hepatitis; chronic hepatitis C; antiviral therapy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

11 (12)

2011.

986-992

objavljeno

1735-143X

10.5812/kowsar.1735143X.779

Povezanost rada

Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita, Psihologija

Poveznice
Indeksiranost